Scandinavian Biopharma’s expansion requires expanded premises

During the pandemic, Scandinavian Biopharma has succeeded in completing and starting several clinical studies, developed an improved formulation for commercial launch and built production capacity together with our contract manufacturers. During the pandemic, the company has hired many new employees in research, clinical development, registration, manufacturing and sales. We continue to grow to achieve our […]

Scandinavian Biopharma strengthens its vaccine portfolio in the field of diarrhoeal disease by in-licencing a Campylobacter vaccine technology from Canadian company, VaxAlta Inc.

Scandinavian Biopharma has strengthened its vaccine portfolio through the addition of an innovative preclinical technology for the development of a new Campylobacter jejuni vaccine. Campylobacter jejuni is one of the most common causes of bacterial diarrhoeal illness in humans. Common sources of Campylobacter jejuni include raw or undercooked poultry, raw milk, raw vegetables, shellfish and […]